Literature DB >> 23183922

Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study.

Jens Claassen, Julian Teufel, Roger Kalla, Rainer Spiegel, Michael Strupp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23183922     DOI： 10.1007/s00415-012-6764-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.

Authors:  M Strupp; R Kalla; J Claassen; C Adrion; U Mansmann; T Klopstock; T Freilinger; H Neugebauer; R Spiegel; M Dichgans; F Lehmann-Horn; K Jurkat-Rott; T Brandt; J C Jen; K Jahn
Journal:  Neurology       Date:  2011-07-06       Impact factor: 9.910

3.  Hereditary paroxysmal ataxia: response to acetazolamide.

Authors:  R C Griggs; R T Moxley; R A Lafrance; J McQuillen
Journal:  Neurology       Date:  1978-12       Impact factor: 9.910

4.  Dalfampridine (Ampyra) for MS.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2010-09-20       Impact factor: 1.909

Review 5.  Primary episodic ataxias: diagnosis, pathogenesis and treatment.

Authors:  J C Jen; T D Graves; E J Hess; M G Hanna; R C Griggs; R W Baloh
Journal:  Brain       Date:  2007-06-15       Impact factor: 13.501

Review 6.  Episodic ataxia type 2.

Authors:  Michael Strupp; Andreas Zwergal; Thomas Brandt
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

7.  Acetazolamide improves neurotological abnormalities in a family with episodic ataxia type 2 (EA-2).

Authors:  Hanna Harno; Timo Hirvonen; Mari A Kaunisto; Heikki Aalto; Hilla Levo; Elina Isotalo; Hannu Somer; Mikko Kallela; Aarno Palotie; Maija Wessman; Markus Färkkilä
Journal:  J Neurol       Date:  2004-02       Impact factor: 4.849

Review 8.  Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.

Authors:  Michael Strupp; Matthew J Thurtell; Aasef G Shaikh; Thomas Brandt; David S Zee; R John Leigh
Journal:  J Neurol       Date:  2011-04-02       Impact factor: 4.849
  8 in total
  11 in total

Review 1.  The treatment and natural course of peripheral and central vertigo.

Authors:  Michael Strupp; Marianne Dieterich; Thomas Brandt
Journal:  Dtsch Arztebl Int       Date:  2013-07-22       Impact factor: 5.594

Review 2.  The Clinical Spectrum of Autosomal-Dominant Episodic Ataxias.

Authors:  Stefan Kipfer; Michael Strupp
Journal:  Mov Disord Clin Pract       Date:  2014-07-28

Review 3.  Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.

Authors:  Katharina Feil; Tatiana Bremova; Carolin Muth; Roman Schniepp; Julian Teufel; Michael Strupp
Journal:  Cerebellum       Date:  2016-02       Impact factor: 3.847

Review 4.  The physiological basis of therapies for cerebellar ataxias.

Authors:  Hiroshi Mitoma; Mario Manto
Journal:  Ther Adv Neurol Disord       Date:  2016-05-20       Impact factor: 6.570

Review 5.  Aminopyridines for the treatment of neurologic disorders.

Authors:  Michael Strupp; Julian Teufel; Andreas Zwergal; Roman Schniepp; Kamran Khodakhah; Katharina Feil
Journal:  Neurol Clin Pract       Date:  2017-02

6.  Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-Controlled Trial.

Authors:  Carolin Muth; Julian Teufel; Ludger Schöls; Matthis Synofzik; Christiana Franke; Dagmar Timmann; Ulrich Mansmann; Michael Strupp
Journal:  Neurol Clin Pract       Date:  2021-08

Review 7.  [Peripheral, central and functional vertigo syndromes].

Authors:  M Strupp; M Dieterich; A Zwergal; T Brandt
Journal:  Nervenarzt       Date:  2015-12       Impact factor: 1.214

8.  Consensus paper: management of degenerative cerebellar disorders.

Authors:  W Ilg; A J Bastian; S Boesch; R G Burciu; P Celnik; J Claaßen; K Feil; R Kalla; I Miyai; W Nachbauer; L Schöls; M Strupp; M Synofzik; J Teufel; D Timmann
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

9.  Therapies for ataxias.

Authors:  Laurence Martineau; Anne Noreau; Nicolas Dupré
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

10.  [Cardinal symptom vertigo from the neurologist's perspective].

Authors:  M Strupp; C Muth; N Böttcher; O Bayer; J Teufel; K Feil; T Bremova; O Kremmyda; C S Fischer
Journal:  HNO       Date:  2013-09       Impact factor: 1.284
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.